Clinical evaluation of [18F]THK5351 in neurological disorder

Clinical evaluation of [18F]THK5351 in neurological disorder - Clinical evaluation of [18F]THK5351 in neurological disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000043744

Enrollment

500

Registered

2021-03-25

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurological disorder

Interventions

[18F]THK5351 PET/CT studies will be performed in patients. PET images of the brain will be acquired 50 min after intravenous injection of 3.7 MBq/kg [18F]THK5351.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Neurological disorders

Exclusion criteria

Exclusion criteria: 1) Pregnant, possibly pregnant 2) Subject who is facing a life crisis 3) Subject who was judged by the investigator to be inappropriate as a participant in this study

Design outcomes

Primary

Measure	Time frame
Uptake of Fluorine-18-labeled THK5351 PET	—

Countries

Japan

Contacts

Public ContactYuka Yamamoto

Faculty of Medicine, Kagawa University Radiology

yamamoto.yuka@kagawa-u.ac.jp0878985111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026